Trelegy Ellipta, a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist ...
China: Severe asthma remains a major healthcare challenge, contributing to increased morbidity, reduced quality of life, and ...
A new study published in the CHEST journal found that ensifentrine, an innovative inhaled therapy, significantly reduces the ...
Enerzair (formerly QVM149) consists of long-acting beta agonist (LABA) indacaterol, long-acting muscarinic antagonist (LAMA) glycopyrronium, and inhaled corticosteroid (ICS) mometasone furoate ...
The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ...
Illinois Municipal Retirement Fund increased its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...
a long-acting beta2-adrenergic agonist (LABA), delivered in a single once-daily dose in GSK’s Ellipta dry powder inhaler. Novartis says its results support recommendations put forward by the ...
Inhaled corticosteroids; LABA: Long-acting β 2-agonists; PEF: Peak expiratory flow; Pre-BD: Value measured prebronchodilator; PY: Pack-years; Raw: Airway resistance. In the last 5 years ...
SMART is a treatment where patients use one inhaler that includes both an inhaled corticosteroid (ICS) and a specific long-acting bronchodilator (LABA), called formoterol. This is how one inhaler can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback